Eli Lilly and Company at Morgan Stanley Global Healthcare Conference Transcript

gurufocus.com · 2026-09-15

Sep 14, 2026 / 05:50PM GMTTerence Flynn - Morgan Stanley & Co Ltd - Analyst All right. Thanks so much everyone. I'm Terence Flynn, Morgan Stanley's US biopharma

TickrTrends take: Eli Lilly's participation in the Morgan Stanley Global Healthcare Conference provides an opportunity for investors to assess management commentary against TickrTrends' current undervalued designation for the company. Valuation-focused readers should monitor what specific pipeline developments, revenue forecasts, and competitive positioning the company discusses, as these factors directly influence whether the undervaluation thesis remains justified. Given LLY's position in the Healthcare sector, any forward-looking statements about drug approvals, market share, or margin expansion could materially impact the gap between current valuation and intrinsic value.

Read the full story at gurufocus.com →